2023 annual financial data
BioRestorative Therapies 2023 Operating cash flow growth
Direct answer
Operating cash flow growth was -8.75%.
Operating income was -15,220,774 USD and net income was -10,417,704 USD.
Operating cash flow was -6,430,211 USD.
Get free BioRestorative Therapies email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 145,800 USD
- Operating income
- -15,220,774 USD
- Net income
- -10,417,704 USD
- Operating cash flow
- -6,430,211 USD